Anavex Life Sciences

AVXLNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
2.57 USD
↘ 0.25 (8.87%)AT CLOSE (11:59 AM EDT)
2.61
↗ 0.04 (1.36%)
POST MARKET (AS OF 07:22 PM EDT)
Post Market
AS OF 07:22 PM EDT
2.61
↗ 0.04 (1.36%)
🔴Market: CLOSED
Open?$2.82
High?$2.82
Low?$2.56
Prev. Close?$2.82
Volume?942.4K
Avg. Volume?1.0M
VWAP?$2.64
Rel. Volume?0.90x
Bid / Ask
Bid?$2.63 × 200
Ask?$2.90 × 10.0K
Spread?$0.27
Midpoint?$2.76
Valuation & Ratios
Market Cap?238.2M
Shares Out?92.7M
Float?87.8M
Float %?94.8%
P/E Ratio?N/A
P/B Ratio?1.88
EPS?-$0.43
Dividend?0.00%
Ex-Dividend?N/A

Shares of Anavex Life Sciences (AVXL) are trading at $2.57. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, AVXL appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Themes
Biotech - Drug Development›Neuroscience & CNSHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
34
Market Cap
238.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.anavex.com
Listed
2006-08-02
Address
630 5TH AVENUE
NEW YORK, NY 10111
Phone: 844-689-3939
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
65
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?18.39Safe
Confidence?40%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.90%Squeeze Risk
Short Interest?19.2M
Days to Cover?19.6
Free Float87.8M
Avg Daily Volume980.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?23.89Strong
Quick Ratio?23.89Strong
Cash Ratio?23.67Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
77
1.88CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
6
-31.6%WEAK▾
ROA?
S&P
3
-30.0%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$106.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist